HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class I

AIDS Research and Human Retroviruses

Volumn 18, Issue 17, 2002, Pages 1319-1325

  Kutsch, Olaf ^a,c   Vey, T ^b   Kerkau, T ^a   Hunig T ^a   Schimpl, A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN TAP; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REGULATORY MECHANISM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; DOWN-REGULATION; ENDOPLASMIC RETICULUM; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; PROTEIN TRANSPORT; T-LYMPHOCYTES, CYTOTOXIC; VIRAL INTERFERENCE;

EID: 0036933169     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202320886361     Document Type: Article

References (35)

1. Johnson WE and Desrosiers RC: Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 2002;53:499-518.
2. McMichael AJ and Phillips RE: Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997;15:271-296.
3. Blankson JN, Persaud D, and Siliciano RF: The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002;53:557-593.
4. Gandhi RT and Walker BD: Immunologic control of HIV-1. Annu Rev Med 2002;53:149-172.
5. Cresswell P, Bangia N, Dick T, and Diedrich G: The nature of the MHC class I peptide loading complex. Immunol Rev 1999;172:21-28.
6. Reits EA, Vos JC, Gromme M, and Neefjes J: The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000;404:774-778.
7. Powis S J, Townsend AR, Deverson EV, Bastin J, Butcher GW, and Howard JC: Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature 1991;354:528-531.
8. Vos JC, Spee P, Momburg F, and Neefjes J: Membrane topology and dimerization of the two subunits of the transporter associated with antigen processing reveal a three-domain structure. J Immunol 1999;163: 6679-6685.
9. Androlewicz MJ: The role of tapasin in MHC class I antigen assembly. Immunol Res 1999;20:79-88.
10. Li S, Paulsson KM, Sjogren HO, and Wang P: Peptide-bound major histocompatibility complex class I molecules associated with tapasin before dissociation from transporter associated with antigen processing. J Biol Chem 1999;274:8649-8654.
11. Androlewicz MJ: Peptide generation in the major histocompatibility complex class I antigen processing and presentation pathway. Curr Opin Hematol 2001;8:12-16.
12. De Silva AD, Boesteanu A, Song R, Nagy N, Harhaj E, Harding CV, and Joyce S: Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides. J Immunol 1999;163: 4413-4420.
13. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, Peterson PA, Yang Y, and Fruh K: The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6:613-621.
14. Lehner PJ, Karttunen JT, Wilkinson GW, and Cresswell P: The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA 1997;94:6904-6909.
15. Hewitt EW, Gupta SS, and Lehner PJ: The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J 2001;20:387-396.
16. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, and Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-415.
17. Tomazin R, Hill AB, Jugovic P, York I, van Endert P, Ploegh HL, Andrews DW, and Johnson DC: Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 1996; 15:3256-3266.
18. Howcroft TK, Strebel K, Martin MA, and Singer DS: Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 1993;260:1320-1322.
19. Kerkau T, Bacik I, Bennink JR, Yewdell JW, Hunig T, Schimpl A, and Schubert U: The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997;185:1295-1305.
20. Collins KL, Chen BK, Kalams SA, Walker BD, and Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
21. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, and Schwartz O: Nef interacts with the mu subunit of clathfin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998;8:483-495.
22. Le Gall S, Buseyne F, Trocha A, Walker BD, Heard JM, and Schwartz O: Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation. J Virol 2000;74:9256-9266.
23. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, and Baltimore D: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-671.
24. Schwartz O, Marechal V, Le Gall S, Lemonnier F, and Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nature Med 1996;2:338-342.
25. Swann SA, Williams M, Story CM, Bobbitt KR, Fleis R, and Collins KL: HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 2001;282:267-277.
26. Neefjes JJ, Momburg F, and Hammerling GJ: Selective and ATPdependent translocation of peptides by the MHC-encoded transporter. Science 1993;261:769-771.
27. Hosken NA and Bevan MJ: Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science 1990;248:367-370.
28. Hosken NA and Bevan MJ: An endogenous antigenic peptide bypasses the class I antigen presentation defect in RMA-S. J Exp Med 1992;175:719-729.
29. Kerkau T, Gernert S, Kneitz C, and Schimpl A: Mechanism of MHC class I downregulation in HIV infected cells. Immunobiology 1992;184:402-409.
30. Scheppler JA, Nicholson JK, Swan DC, Ahmed-Ansari A, and McDougal JS: Down-modulation of MHC-I in a CD4+ T cell line, CEM-E5, after HIV-1 infection. J Immunol 1989;143:2858-2866.
31. Kerkau T, Schmitt-Landgraf R, Schimpl A, and Wecker E: Downregulation of HLA class I antigens in HIV-1-infected cells. AIDS Res Hum Retroviruses 1989;5:613-620.
32. Fruh K, Ahn K, Djaballah H, Sempe P, van Endert PM, Tampe R, Peterson PA, and Yang Y: A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
33. de la Salle H, Hanau D, Fricker D, Urlacher A, Kelly A, Salamero J, Powis SH, Donato L, Bausinger H, Laforet M, et al.: Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 1994;265:237-241.
34. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, and Zweerink H: Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991;174:489-492.
35. Wei ML and Cresswell P: HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992;356:443-446.